Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

283.75USD
23 May 2018
Change (% chg)

$4.06 (+1.45%)
Prev Close
$279.69
Open
$277.14
Day's High
$283.90
Day's Low
$276.74
Volume
601,898
Avg. Vol
657,291
52-wk High
$370.53
52-wk Low
$244.31

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 30.95 32.75
EPS (TTM): 15.23 -- --
ROI: 17.59 14.84 14.38
ROE: 28.64 16.34 16.07

S.Korea stocks, won edge up amid caution on U.S.-China trade talks

* KOSPI index rises, foreigners sell * Korean won inches up versus U.S. dollar * South Korea bond yields down SEOUL, May 18 Round-up of South Korean financial markets: ** South Korea's KOSPI stock index and the Korean won both nudged up on Friday, while investors remained cautious as they watch how the U.S.-Sino trade negotiations unfold. ** Market players also eyed developments of talks between the United States and North Korea. U.S. President Donald T

18 May 2018

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.

17 May 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

02 May 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion (4.4 billion pounds) in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

02 May 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

02 May 2018

BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMER'S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB

01 May 2018

BRIEF-Biogen CEO Michel Vounatsos' Total Compensation For 2017 Was $13.7 Million

* BIOGEN SAYS CEO MICHEL VOUNATSOS' TOTAL COMPENSATION FOR 2017 WAS $13.7 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KjjpbG) Further company coverage:

27 Apr 2018

Biogen's revenue misses as Spinraza sales disappoint

Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment.

24 Apr 2018

UPDATE 3-Biogen's revenue misses as Spinraza sales disappoint

* Biogen shares pare losses (Adds conference call, analysts comments; updates shares)

24 Apr 2018

Biogen quarterly profit jumps on higher Spinraza sales

April 24 Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.

24 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.45 +0.54
Pfizer Inc. (PFE.N) $35.97 +0.25
Novartis AG (NOVN.S) CHF76.16 -0.52
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Roche Holding Ltd. (ROG.S) CHF219.25 -4.65
Roche Holding Ltd. (RO.S) CHF223.40 -5.40
Bayer AG (BAYGn.DE) €102.74 -2.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.23 -0.14
GlaxoSmithKline plc (GSK.L) 1,507.60 -1.60

Earnings vs. Estimates